Related Experiment Video

Updated: Jul 27, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K

A Pan-KRAS Inhibitor Impedes Common KRAS Oncoproteins and Tumor Growth

    Cancer Discovery
    |June 9, 2023
    PubMed

    Insights

    A novel pan-RAS inhibitor targets the inactive state of KRAS mutants, offering potential therapeutic benefits. This selective inhibitor spares other RAS isoforms, minimizing off-target effects.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Drug Discovery

    Background:

    • KRAS mutations are prevalent in various cancers, driving tumor growth.
    • Targeting KRAS remains a significant challenge in cancer therapy.
    • Existing therapies often lack specificity, leading to side effects.

    Purpose of the Study:

    • To develop a novel inhibitor targeting multiple KRAS mutants.
    • To assess the selectivity of the inhibitor for KRAS over other RAS isoforms.
    • To evaluate the potential of this inhibitor as a cancer therapeutic.

    Main Methods:

    • In vitro biochemical assays to assess inhibitor binding and activity.
    • Cell-based assays to evaluate the inhibitor's effect on KRAS signaling.
    • Structural biology studies to understand inhibitor-target interactions.

    Main Results:

    • The pan-KRAS inhibitor demonstrated potent activity against multiple KRAS mutants.
    • The inhibitor selectively binds to the inactive conformation of KRAS.
    • Off-target effects on other RAS isoforms (HRAS, NRAS) were minimal.

    Conclusions:

    • A novel pan-KRAS inhibitor has been identified with high selectivity for KRAS mutants.
    • This inhibitor's selectivity for the inactive state offers a promising therapeutic strategy.
    • Further development of this inhibitor could lead to new cancer treatments.

    More Related Videos

    Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion09:23

    Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion

    Published on: April 2, 2020

    6.5K
    Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

    Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

    Published on: October 5, 2020

    3.1K

    Related Concept Videos

    The Ras Gene02:38

    The Ras Gene

    The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
    Ras is a...
    6.3K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    3.8K
    Small GTPases - Ras and Rho01:24

    Small GTPases - Ras and Rho

    Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
    Three regulatory proteins control their activity:
    4.0K
    PI3K/mTOR/AKT Signaling Pathway01:22

    PI3K/mTOR/AKT Signaling Pathway

    The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
    3.7K
    Cancer-Critical Genes I: Proto-oncogenes01:33

    Cancer-Critical Genes I: Proto-oncogenes

    Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
    When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
    Such genes that act...
    9.0K
    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    6.6K